STOCK TITAN

[15-12G] Merus N.V. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
15-12G

Rhea-AI Filing Summary

Analyzing...
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-37773

 

 

 

Merus N.V.

(Exact name of registrant as specified in its charter)

 

 

Uppsalalaan 17

3584 CT Utrecht

The Netherlands

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Shares, €0.09 nominal value per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

 

Rule 12g-4(a)(2)

 

Rule 12h-3(b)(1)(i)

 

Rule 12h-3(b)(1)(ii)

 

Rule 15d-6

 

Rule 15d-22(b)

 

Approximate number of holders of record as of the certification or notice date: Zero (0).

Pursuant to the requirements of the Securities Exchange Act of 1934, Merus B.V. (as successor to Merus N.V.) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: January 9, 2026    

Merus B.V.

as successor to Merus N.V.

    By:   /s/ Jan G. J. van de Winkel
    Name:   Jan G. J. van de Winkel
    Title:   Managing Director

 

 
 
Merus

NASDAQ:MRUS

MRUS Rankings

MRUS Latest News

MRUS Latest SEC Filings

MRUS Stock Data

6.83B
918.24k
2.29%
103.79%
5.77%
Biotechnology
Pharmaceutical Preparations
Link
Netherlands
3584 CM UTRECHT